Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 4/20 | 0.54 |
| ▸ | SIRT6 | Q8N6T7 | 5/20 | 0.53 |
| ▸ | HTR6 | P50406 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2593352 | 0.86 | MAPT (0.49) | CHEK1ALDH1A1HTR2AMAPTLMNA | |
| SCHEMBL2593407 | 0.82 | HTR2A (0.56) | CHEK1ALDH1A1HTR2A | |
| SCHEMBL14768412 | 0.82 | HTR2A (0.54) | ALDH1A1HTR2APOLBLMNA | |
| SCHEMBL2589906 | 0.76 | HTR2A (0.52) | CHEK1ALDH1A1HTR2A | |
| SCHEMBL16206580 | 0.74 | ALDH1A1 (0.46) | HTR6ALDH1A1HTR2AMAPTLMNA | |
| SCHEMBL14968913 | 0.74 | HTR2A (0.57) | HTR6ALDH1A1HTR2APOLBLMNA | |
| SCHEMBL30068242 | 0.73 | HTR2A (0.65) | ALDH1A1HTR2A | |
| SCHEMBL30068289 | 0.73 | HTR2A (0.65) | ALDH1A1HTR2A | |
| SCHEMBL12184182 | 0.73 | CHEK1 (0.81) | CHEK1 | |
| SCHEMBL27173101 | 0.72 | HTR2A (0.64) | ALDH1A1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716287-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (GB) | 2014-05-06 | — | — | US | disclosed |
| EP-2569290-A2 | PHARMACEUTICAL COMPOUNDS | Sentinel Oncology Limited (GB) | 2013-03-20 | — | — | EP | disclosed |
| US-20130065900-A1 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2013-03-14 | — | — | US | disclosed |
| WO-2011141716-A2 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065900-A1 | PHARMACEUTICAL COMPOUNDS | CSNK1A1, FRK, CSNK1E | CHEK1 105/4885SIRT6 2954/4885HTR6 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.